Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi

Saeeda Fouzia Qasim; Tasnim  Ahsan; Saima  Ghaus; Paras Imran

doi:10.12669/pjms.39.4.7353

Saeeda Fouzia Qasim 1. Jinnah Postgraduate Medical Center 2. Medicell Institute of Diabetes, Endocrinology and Metabolism (MIDEM), Karachi, Pakistan
Tasnim Ahsan 1. Jinnah Postgraduate Medical Center 2. Medicell Institute of Diabetes, Endocrinology and Metabolism (MIDEM), Karachi, Pakistan
Saima Ghaus Medicell Institute of Diabetes, Endocrinology and Metabolism (MIDEM), Karachi, Pakistan
Paras Imran 1. Jinnah Postgraduate Medical Center 2. Medicell Institute of Diabetes, Endocrinology and Metabolism (MIDEM), Karachi, Pakistan

DOI: https://doi.org/10.12669/pjms.39.4.7353

Keywords: Diabetes Mellitus, GLP-1RA, Obesity, Glycemic control, HbA1c

Abstract

Objective: To assess the effectiveness of GLP-1RAs in managing obese T2DM patients.

Methods: This prospective cohort analysis was conducted at Medicell Institute of Diabetes, Karachi, Pakistan; from July 2019 to July 2021. A total of 97 obese individuals >16 years of age with T2DM and IGT were initially enrolled, and 81 patients who showed up for the follow-up were prescribed one of the three GLP-1RAs available in Pakistan.

Results: Out of 81 patients who showed up for the follow-up visit, 43 had received Liraglutide, 25 were taking Dulaglutide, and 13 had been prescribed IDegLira supplemented with oral hypoglycemic medications ± insulin. The mean age of the enrolled patients was 49.21(12.44) years, and there was female predominance (55.6%). Overall, there was a significant weight and BMI reduction among the patients treated with either of the GLP-1RAs (P<.01). Furthermore, significant glycemic control was observed in all three groups after the treatment. The Dulaglutide group demonstrated a more significant reduction of HbA1c compared to Liraglutide group, which showed more pronounced weight and BMI reduction. Nevertheless, this class of medications was well-tolerated, with nausea being the most often reported side effect.

Conclusion: GLP-1RAs showed favorable weight and HbA1c reduction among patients of all three treatment groups.

doi: https://doi.org/10.12669/pjms.39.4.7353

How to cite this: Qasim SF, Ahsan T, Ghaus S, Imran P. Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi. Pak J Med Sci. 2023;39(4):1113-1118. doi: https://doi.org/10.12669/pjms.39.4.7353

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.